Liposomal Cisplatin and Procainamide Hydrochloride: Enhanced
2026-05-15
Enhanced Antiproliferative Activity via Liposomal Co-Delivery of Cisplatin and Procainamide Hydrochloride
Study Background and Research Question
Cisplatin (cis-diamminedichloroplatinum(II), DDP) remains a chemotherapy mainstay but is limited by nephrotoxicity and hepatotoxicity, as well as resistance mechanisms in tumor cells. Procainamide hydrochloride, classically a cardiac sodium channel blocker, has been shown to modulate DNA methylation and exert potential chemoprotective effects. Previous studies suggested that procainamide could not only protect normal tissues from cisplatin toxicity but also potentiate its anticancer activity. The central research question addressed by Viale et al. was whether co-encapsulation of cisplatin and procainamide hydrochloride in liposomes could enhance antiproliferative efficacy while reducing off-target toxicity (paper).Key Innovation from the Reference Study
The core innovation was the development and characterization of multilamellar liposomes co-loaded with cisplatin and procainamide hydrochloride. This approach exploits procainamide’s dual function: as a cardiac sodium channel blocker and as an inhibitor of DNA methyltransferase 1, potentially altering tumor cell response to cisplatin. The study uniquely demonstrates that procainamide, when delivered in combination with cisplatin via a liposomal carrier, not only protects against cisplatin-induced organ toxicity but also synergistically enhances antiproliferative activity in vitro (paper).Methods and Experimental Design Insights
Viale et al. prepared multilamellar liposomes using hydration of a lipid film, generating two main formulations: DDP-only liposomes and DDP/procainamide hydrochloride (PA) co-loaded liposomes. Both unfiltered and gel-filtered liposomes were produced to distinguish between drugs embedded within the liposomal aqueous compartments and those present in bulk solution. Liposome size and polydispersity were characterized: DDP-liposomes averaged 327 ± 3 nm, while DDP/PA-liposomes were slightly larger at 465 ± 5 nm, both with polydispersity indices around 0.3 ± 0.1 (paper). Drug loading was quantified spectrophotometrically, revealing efficient co-encapsulation, particularly for procainamide, driven by electrostatic interactions with the negatively charged liposomal surface. Antiproliferative activities were assessed via MTT assays on three human cancer cell lines: ovarian carcinoma (A2780), lung carcinoma (A549), and non-Hodgkin lymphoma (DOHH2). The study carefully compared the effects of DDP and PA both in solution, in combination, and co-loaded in liposomes.Protocol Parameters
- assay | MTT cell viability | applicability: A2780, A549, DOHH2 cell lines | rationale: standard for measuring antiproliferative effects | source: paper
- DDP-liposome diameter | 327 ± 3 nm | applicability: size characterization for drug delivery | rationale: optimal for cellular uptake and circulation | source: paper
- DDP/PA-liposome diameter | 465 ± 5 nm | applicability: co-delivery system | rationale: size increase due to dual drug loading | source: paper
- polydispersity index | 0.3 ± 0.1 | applicability: batch reproducibility | rationale: indicates uniformity in liposomal populations | source: paper
- PA loading (filtered liposomes) | 3.1 ± 0.3 × 10⁻⁴ M | applicability: co-encapsulation efficiency | rationale: maximizes procainamide delivery to target cells | source: paper
- DDP loading (filtered liposomes) | 3.0 ± 1.6 × 10⁻⁵ M | applicability: co-encapsulation efficiency | rationale: ensures relevant cytotoxic dosing | source: paper
- PA working concentration (MTT) | 10–160 μM | applicability: negative controls | rationale: to confirm PA alone is not cytotoxic | source: paper
- procainamide solubility in DMSO | ≥13.65 mg/mL | applicability: stock solution preparation | rationale: ensures compatibility with standard lab protocols | source: product_spec
- procainamide storage conditions | -20°C | applicability: material preservation | rationale: maintains compound stability | source: product_spec
Core Findings and Why They Matter
The study found that procainamide hydrochloride alone did not significantly inhibit proliferation of A549 lung carcinoma cells at concentrations up to 160 μM, confirming its lack of direct cytotoxicity under these conditions. However, when combined with cisplatin—either in solution or co-encapsulated in liposomes—procainamide potentiated cisplatin’s antiproliferative effects. Notably, liposomal DDP/PA formulations exhibited greater efficacy than DDP in solution, with a reduced IC₅₀ for the filtered DDP-liposome group (2.23 ± 0.17 μM) compared to DDP in solution (4.46 ± 0.58 μM) (paper). Mechanistically, the increased loading of procainamide in liposomes is attributed to its cationic nature, which enhances electrostatic binding to the negatively charged liposomal membrane. This not only increases the delivery of procainamide to target cells but also allows for modulation of cisplatin pharmacokinetics and toxicity profiles. Previous studies cited by the authors support procainamide’s ability to reduce cisplatin-induced nephrotoxicity and hepatotoxicity in vivo, likely through altered platinum complex formation and distribution (internal resource). These results are significant for two reasons:- They demonstrate a rational design for combinatorial drug delivery, using procainamide’s established pharmacological properties to both potentiate chemotherapy and mitigate normal tissue toxicity.
- They provide a model for leveraging cardiac sodium channel blockers with secondary effects—such as inhibition of DNA methyltransferase 1—to enhance cancer therapy (internal resource).